The Prognostic Value of PET/CT Following Induction Therapy in Follicular Lymphoma

A new retrospective study demonstrates the prognostic value of PET-CT scans for patients with follicular lymphoma.

Dr. Judith Trotman, reporting at the American Society of Clinical Oncology annual meeting, said that positron emission tomography–computed tomography performed at the end of induction therapy is strongly predictive of both progression-free and overall survival.

Her team analyzed data on 246 PET-CT scans performed following chemoimmunotherapy in three clinical trials. What they found was that patients with 18-fluorodeoxyglucose (FDG) uptake of 4 or greater on the 5-point Deauville scale for postinduction response assessment, had a four times higher risk for disease progression, compared with patients who became PET negative after induction.

At 4.5 years of follow-up, median progression-free survival (PFS) was 16.9 months for patients with a PET uptake of 4 or greater on the scale, versus 74 months for PET-negative patients.

Overall survival at 4.5 years for patients with a higher uptake of FDG PET was 87 percent, compared with 97 percent for patients who were PET negative after induction.

The study results also showed that conventional CT assessment provides only limited additional value, and that "PET-CT applying the 5-point scale should be the new gold standard for therapeutic response assessment in this lymphoma."

Added Dr. Trotman, "We argue that for the patients who remain PET positive, follicular lymphoma is no longer an indolent histology."

Source: ASCO

follicular lymphoma treatment

More Articles

More Articles

In T cell lymphoma, T lymphocytes, which are an essential part of the body's immune response, become malignant. T cell lymphomas account for about...

Lymphomatoid Papulosis (LyP) is a rare skin disorder that involves cancerous looking skin lesions. It is more than a skin condition; it is the...

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is a relatively rare B-cell subtype of non-Hodgkin'...

T-Cell Lymphoblastic Lymphoma (T-LBL) is a very rare subtype of non-Hodgkin's lymphoma. It tends to develop in...

In general, a diagnosis of T-cell lymphoma denotes a poorer prognosis than a diagnosis of B-cell lymphoma. One of...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...